A Phase II Evaluation of Intraperitoneal EGEN-001 (IL-12 Plasmid Formulated With PEG-PEI-Cholesterol Lipopolymer) in the Treatment of Persistent or Recurrent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer
Latest Information Update: 12 Aug 2024
At a glance
- Drugs IMNN 001 (Primary)
- Indications Carcinoma; Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
- Focus Adverse reactions; Therapeutic Use
Most Recent Events
- 07 Aug 2024 According to an Imunon media release, company announces that the Company will host a conference call at 11:00 a.m. ET on Wednesday, August 14, 2024 to discuss financial results for the second quarter ended June 30, 2024 and provide an update on this trial.
- 23 Mar 2023 According to an Imunon media release, company will host a conference call at 11:00 a.m. ET on Thursday, March 30, 2023 to provide an update on its clinical development of IMNN-001 in Phase 2 clinical development for the treatment of advanced-stage ovarian cancer.
- 03 May 2017 Status changed from active, no longer recruiting to completed.